3-Year Supporting Data on TAVI in Low-Risk Patients: EVOLUT

Published Date: 08 Mar 2023

3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery

Read Full News

Latest News

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Extensive Screen Time Tied to CV Risk

Screen time is identified as an independent cardiovascular risk factor in an observational study of young adults living in Pakistan.

Knowledge Areas: Transforming Hospital Care

Vall d’Hebron reorganized care into Knowledge Areas; the Heart Area pilot cut length of stay by 18%, 30-day readmissions by 12%, and in-hospital mortality by 48% — early but promising.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Latest News

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Screen time is identified as an independent cardiovascular risk factor in an observational study of young adults living in Pakistan.

Vall d’Hebron reorganized care into Knowledge Areas; the Heart Area pilot cut length of stay by 18%, 30-day readmissions by 12%, and in-hospital mortality by 48% — early but promising.

News All Time

Few Prescribing for Elevated Lp(a) in Low-Risk Patients

Most clinicians take no preventive action when a low-risk patient presents with elevated levels of lipoprotein(a), but 1 in 5 clinicians initiate preventive pharmacotherapy.

New Tool Predicts Cardiometabolic Risk in Psychosis

A web-based risk prediction tool can forecast weight gain, metabolic syndrome, and diabetes years in advance in young adults with psychosis, which may provide an opportunity for earlier intervention.

What Is Delaying Movement in Managing Gastroparesis?

Differing perspectives among gastric motility experts and regulatory roadblocks impede clinical care, but some companies are moving forward.

Ultraprocessed Foods Increase Risk of Heart Problems

Each serving of ultraprocessed food increased risk of cardiac events by 5%.

Inflammation May Explain Link Between Belly Fat, HF

Excess abdominal fat — not overall body weight — may drive heart failure risk, with systemic inflammation being partially to blame.

In High-BP Patients, Lifestyle Tied to Cardiometabolic Risk

Maintaining a healthy lifestyle was associated with a lower risk for major cardiometabolic diseases, regardless of antihypertensive medication use.

Arterial Stiffness Changes Linked to Developing Dementia

Pulse wave velocity, calculated from age and blood pressure changes, was associated with significant dementia risk in a post hoc SPRINT analysis.

Tool Spots Heart Failure Risk Missed in Patients With ASCVD

A risk model predicts the risk for heart failure in patients with atherosclerotic cardiovascular disease and flags a notable proportion classified as low risk by other risk tools.

Triple Agonist Retatrutide Reduces A1c, Weight in T2D

Eli Lilly and Company report top-line phase 3 clinical trial results for its investigational GLP-1, GIP, and glucagon agonist in people with type 2 diabetes.

Are Nursing Homes Misprescribing Antipsychotics?

The HHS Inspector General claims that some nursing homes are inappropriately diagnosing residents with schizophrenia and prescribing antipsychotics without proper oversight.

High Blood Pressure Is Risky, Even for Young Adults

Young adults with systolic blood pressure that is 10 points higher than that of their peers have a 27% greater risk for heart disease and a 22% greater risk for kidney disease after age 40.

Light Activity May Reduce HBP Risk in Pregnancy

No need for strenuous exercise: Consistent, daily light activity can reduce hypertension risk in pregnant women by 30%.

CAC Still Predicts Heart Risk When Lp(a) Is High

An observational study shows the two factors to be independent predictors of atherosclerotic cardiovascular disease.

Is ‘Good’ Cholesterol Really Good? HDL Role Evolving

Both low and extremely high HDL cholesterol levels may increase cardiovascular risk.

HIV Status Affects Pregnancy-Related Cardiac Changes

Pregnancy history is associated with significant differences in cardiac structure and function, which vary by HIV status.

Premature Menopause Linked With Greater Risk for CHD

Menopause before age 40 is correlated with a much greater risk for coronary heart disease, and therefore cardiologists should consider earlier preventive measures for this population.

Recommended News For You

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

Asymptomatic or Minimally Symptomatic Myelofibrosis

PSMA PET Beats MRI in Prostate Cancer Staging Study

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

Does diabetes impact the prognosis of people with colorectal cancer?

FDA Approves CAR-T Product Use for Myeloma Early.

Recommended Articles For You

The benefits and risks of taking fludrocortisone for adrenal insufficiency  

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective 

AI in Genomics: Decoding the Human Genome for Cancer Treatment 

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of cancer is decreased by following international health recommendations.

2.

Resection for Early Liver Cancer Tied to Improved Survival.

3.

Healthcare in the Mix in President Biden's Farewell Address

4.

According to new studies, some cancer patients can safely forego radiation therapy.

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

1.

The Cutting-Edge of Phlebectomy: Redefining Vein Care

2.

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring

3.

Ultimate Guide to Oncology Services in the USA

4.

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review

5.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

5.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot